WHO COVID-19 trial moves ahead with three drug candidates

By Jenni Spinner contact

- Last updated on GMT

(BlackJack3D/iStock via Getty Images Plus)
(BlackJack3D/iStock via Getty Images Plus)

Related tags: COVID-19, Coronavirus, World health organization, WHO, Clinical trials, Novartis, Ipca Laboratories, Johnson & johnson

The World Health Organization’s Solidarity PLUS trial will kick off in 52 countries, trialing three drugs to treat patients hospitalized with COVID-19.

The World Health Organization (WHO) is ready for the next phase in its Solidarity trial, designed to come up with viable drug candidates to treat COVID-19. The Solidarity PLUS study is poised to enroll hospitalized COVID-19 patients in 52 different countries in order to test three therapies: artesunate, imatinib, and infliximab.

Candidate selection

According to WHO, the three drugs (donated by their respective manufacturers) were identified and selected by an independent panel of life-science experts, selected for their potential to reduce the risk of death in severe COVID-19 patients. All three are in circulation for other candidates: artesunate for severe malaria, imatinib for a range of cancers, and infliximab for immune-related diseases (including Crohn’s and rheumatoid arthritis).

Finding more effective and accessible therapeutics for COVID-19 patients remains a critical need, and WHO is proud to lead this global effort,​” said Tedros Adhanom Ghebreyesus, WHO director-general. “I would like to thank the participating governments, pharmaceutical companies, hospitals, clinicians, and patients, who have come together to do this in true global solidarity.​”

Solidarity PLUS reportedly represents the largest global collaboration among WHO member states, involving thousands of researchers in more than 600 hospitals across the 52 countries. The structure enables the trial to evaluate multiple treatments at once under a single protocol, and to add new treatments or drop ineffective ones during the course of the study.

In earlier stages of the Solidarity study, researchers evaluated four other drugs: remdesivir, hydroxychloroquine, lopinavir, and interferon. According to researchers, the quartet of therapies had little or no effect on hospitalized COVID-19 patients.

About the drugs

Artesunate, produced by Ipca, is used to treat malaria. During the Solidarity PLUS study, the drug will be administered intravenously for seven days, using the standard dose recommended for the treatment of severe malaria.

Novartis’s Imatinib typically is used to treat cancers. The trial team will administer the drug orally once daily for two weeks.

Infliximab, produced by Johnson and Johnson, is commonly used to treat immune-system disease. IT will be administered via IV in a single dose.

Related news

Show more

Related products

show more

How clinical trial software can optimize trials

How clinical trial software can optimize trials

Formedix | 20-Jun-2022 | Technical / White Paper

This article explains the different types of clinical trial software available, and how it can be used to optimize the end to end clinical trials design...

Strategic Approach to Immunogenicity Assessment

Strategic Approach to Immunogenicity Assessment

Altasciences | 17-May-2022 | Technical / White Paper

In this issue of The Altascientist we provide a detailed overview on the different goals and challenges that are presented by the validation of immunogenicity...

Governing and Maintaining Clinical Data Standards

Governing and Maintaining Clinical Data Standards

Veeva | 10-May-2022 | Technical / White Paper

Investing in data standards plays a huge role in improving the quality of clinical studies. But often, people don’t use the standards correctly, there...

What the Best Clinical Study Build Pros Do

What the Best Clinical Study Build Pros Do

Formedix | 09-May-2022 | Technical / White Paper

Getting your clinical study designed and built ready for data collection takes A LOT of work and expertise… you've got to do all your CRF designs;...

Related suppliers

Follow us

Products

View more

Webinars